Abstract
Acalabrutinib was approved bythe U.S. Food and Drug Administration (FDA) for treatment-naive (TN) and relapsed/refractor)/(R/R) use for patients with ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
